Change - Announcement of Appointment::Change - Announcement of Appointment

Issuer & Securities

Issuer/ Manager
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
Securities
TIANJIN PHARM DA REN TANG GRP - CNE100000924 - T14
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
22-Aug-2022 19:41:05
Status
New
Announcement Sub Title
Change - Announcement of Appointment
Announcement Reference
SG220822OTHRH7LA
Submitted By (Co./ Ind. Name)
Jiao Yan
Designation
Secretary to the Board
Description (Please provide a detailed description of the event in the box below)
Announcement of Appointment of General Manager

Additional Details

Date Of Appointment
22/08/2022
Name Of Person
Wang Lei
Age
51
Country Of Principal Residence
China
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
Approve of the decision
Whether appointment is executive, and if so, the area of responsibility
Duties as a General Manager of the Company
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
General Manager
Professional qualifications
Senior Engineer
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
NIL
Conflict of interests (including any competing business)
NIL
Working experience and occupation(s) during the past 10 years
Ms. Wang joined the Company in July 1993, and successively worked in Da Ren Tang Pharmaceutical Factory, the Planning Office of Chinese Patent Medicine Department of the Company, the Industry Department of the Company, and Le Ren Tang Pharmaceutical Factory. From May 2013 to June 2013, Ms. Wang was a member of the Supervisory Committee of the Company, and from June 2014 to March 2018, she successively served as Deputy General Manager and General Manager of the Company. Ms. Wang was also a Director of the Company from May 2015 to May 2018. Since March 2018, she has successively served as Executive Deputy General Manager, General Manager and Vice Chairman of Tianjin Da Ren Tang Jingwanhong Pharmaceutical Co., Ltd.. Since January 2022 to present, Ms. Wang served as the Deputy General Manager of the Marketing Management Centre of Tianjin Pharmaceutical Holdings Co., Ltd..
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
No
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Ms. Wang was also a Director of the Company from May 2015 to May 2018.
Present
NIL
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
Yes
If Yes, Please provide details of prior experience
Ms. Wang was also a Director of the Company from May 2015 to May 2018.